News - Pharmaphorum

Trending

Latest News

in News News
Scancell expands cancer research deal with Karolinska Institute
August 10, 2018 Share
X
Scancell expands cancer research deal with Karolinska Institute
https://pharmaphorum.com/news/scancell-expands-cancer-research-deal-karolinska/
in News News
UK’s Artios raises $84m to further DDR drug research
August 10, 2018 Share
X
UK’s Artios raises $84m to further DDR drug research
https://pharmaphorum.com/news/uks-artios-raises-84m-to-further-ddr-drug-research/

More news

FDA grants leukaemia drug ‘breakthrough’ status

A leukaemia drug has been granted ‘breakthrough therapy’ status by the US drug regulator. Daiichi Sankyo announced that

X

FDA grants leukaemia drug ‘breakthrough’ status

https://pharmaphorum.com/market-access-2/fda-grants-leukaemia-drug-breakthrough-status/

NHS saved £324 million by switching to biosimilars and generics

The UK’s national healthcare provider saved £324 million by switching its patients to “better value” biosimilar and generic

X

NHS saved £324 million by switching to biosimilars and generics

https://pharmaphorum.com/news/nhs-saved-millions-switching-biosimilars/

Pfizer wins Herceptin biosimilar approval in Europe

European Commission (EC) has approved Pfizer’s Trazimera, for breast and gastric cancer treatment, marking it as pharma’s first

X

Pfizer wins Herceptin biosimilar approval in Europe

https://pharmaphorum.com/news/herceptin-biosimilar-european-approval/

EU regulators reject new use for Opdivo, as Keytruda edges ahead

Keytruda begins to win battle of the immunotherapies

X

EU regulators reject new use for Opdivo, as Keytruda edges ahead

https://pharmaphorum.com/news/eu-regulators-reject-new-use-for-opdivo-as-keytruda-edges-ahead/

Gilead needs deal-maker CEO after Milligan quits

Gilead may be looking for a deal-broker who can kick-start the company’s growth after the lacklustre launch of

X

Gilead needs deal-maker CEO after Milligan quits

https://pharmaphorum.com/news/gilead-needs-deal-maker-ceo-after-milligan-quits-analyst/

Celgene plans filing for Revlimid/rituximab in lymphoma

Filings planned in early 2019

X

Celgene plans filing for Revlimid/rituximab in lymphoma

https://pharmaphorum.com/news/celgene-plans-filing-for-revlimid-rituximab-in-lymphoma/

FDA approves second Neupogen biosimilar

Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA

X

FDA approves second Neupogen biosimilar

https://pharmaphorum.com/news/fda-approves-second-neupogen-biosimilar/

Gilead develops solid tumour cell therapy with Gadeta

Gilead has option to buy biotech if things go well

X

Gilead develops solid tumour cell therapy with Gadeta

https://pharmaphorum.com/news/gilead-develops-solid-tumour-cell-therapy-with-gadeta/

AbbVie raises hopes for blood cancer patients

AbbVie has filed its Venclexta (venetoclax) for a new use that it hopes could change the treatment of

X

AbbVie raises hopes for blood cancer patients

https://pharmaphorum.com/news/venetoclax-abbvie-raises-hopes-blood-cancer-patients/

Taking lenient stance, NICE backs neuroblastoma drug

Body makes special case due to rarity of the disease

X

Taking lenient stance, NICE backs neuroblastoma drug

https://pharmaphorum.com/news/taking-lenient-stance-nice-backs-neuroblastoma-drug/

BMS immunotherapy combo approved in new colorectal use

Bristol-Myers Squibb’s Opdivo and Yervoy has become the first approved immunotherapy combination option for a group of patients

X

BMS immunotherapy combo approved in new colorectal use

https://pharmaphorum.com/news/bms-immunotherapy-combo-approved-in-new-colorectal-use/

Fotivda approved in Scotland for kidney cancer

The Scottish Medicines Consortium (SMC) has recommended regular NHS funding for EUSA Pharma’s kidney cancer drug Fotivda, enabling

X

Fotivda approved in Scotland for kidney cancer

https://pharmaphorum.com/news/fotivda-scotland-kidney-cancer/

NICE rejects BMS immunotherapy in advanced bladder cancer

No review for three years after final guidance

X

NICE rejects BMS immunotherapy in advanced bladder cancer

https://pharmaphorum.com/news/nice-rejects-opdivo-in-advanced-bladder-cancer/

Roche to file Tecentriq in triple negative breast cancer

No other immunotherapies are approved in indication

X

Roche to file Tecentriq in triple negative breast cancer

https://pharmaphorum.com/news/roche-files-tecentriq-triple-negative-breast-cancer/

EU regulators back BMS’ Opdivo in new skin cancer use

Bristol-Myers Squibb’s cancer immunotherapy Opdivo is likely to gain another use in Europe after regulators recommended it after

X

EU regulators back BMS’ Opdivo in new skin cancer use

https://pharmaphorum.com/news/eu-regulators-back-bms-opdivo-in-new-skin-cancer-use/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com